Eidos Therapeutics

YTD

ALL

Why Robinhood?

You can watch EIDX and buy or sell other stocks, ETFs, and their options commission-free!

About EIDX

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR.

CEO

Neil Kumar, PhD

CEONeil Kumar, PhD

Employees

—

Employees—

Headquarters

San Francisco, California

HeadquartersSan Francisco, California

Founded

2013

Founded2013

Employees

—

Employees—

EIDX Key Statistics

Market cap

4.75B

Market cap4.75B

Price-Earnings ratio

-46.10

Price-Earnings ratio-46.10

Dividend yield

—

Dividend yield—

Average volume

138.46K

Average volume138.46K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$132.54

52 Week high$132.54

52 Week low

$28.39

52 Week low$28.39

People also own

Based on the portfolios of people who own EIDX. This list is generated using Robinhood data, and it’s not a recommendation.